In the context of AD, where neuroinflammation and neurotoxicity are prominent pathological hallmarks, the modus operandi of NLY01 offers a potential therapeutic avenue to mitigate analogous pathological mechanisms inherent to this neurodegenerative condition.430 GLP-1RAs and PD PD is a chronic neurodegenerative disorder that affects the CNS and is the second most prevalent neurodegenerative disease worldwide.14 GLP-1RAs are promising pharmacological agents for treating PD due to their potential to preserve the integrity and function of dopaminergic neurons
GLP-1 is contraindicated in patients including but not limited to: those with a personal or family history of medullary thyroid cancer, patients with multiple endocrine neoplasia type 2, patients with a hypersensitivity reaction to GLP-1 or any of the product components, as well as patients with pancreatitis, kidney disease, diabetic retinopathy or gallbladder disease
De Ldinghen V, Heresbach D, Fourdan O, et al
The breadth of DSIPs biological activity spanning sleep regulation, stress modulation, pain processing, antioxidant defence, and neuroprotection has led some researchers to characterise it as an adaptogenic peptide: one that supports homeostatic balance across multiple physiological systems rather than acting on a single discrete target
Mild exfoliation: helps remove dead skin cells for a smoother surface without harsh abrasion